451
Participants
Start Date
February 29, 2012
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Lixisenatide (AVE0010)
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Self-injector pen device (OptiClik®)
Metformin
To be kept at stable dose (≥1.5 g/day) throughout the study.
Investigational Site Number 804102, Kiev
Investigational Site Number 203102, Prague
Investigational Site Number 203101, Prague
Investigational Site Number 203105, Prague
Investigational Site Number 276107, Berlin
Investigational Site Number 724107, A Coruña
Investigational Site Number 724102, Ferrol
Investigational Site Number 724106, Málaga
Investigational Site Number 203104, Pilsen
Investigational Site Number 276103, Aßlar
Investigational Site Number 250105, Rennes
Investigational Site Number 804106, Poltava
Investigational Site Number 724108, Segovia
Investigational Site Number 724105, Seville
Investigational Site Number 840120, Flint
Investigational Site Number 804104, Mykolaiv
Investigational Site Number 203103, Trutnov
Investigational Site Number 840111, Fargo
Investigational Site Number 840115, Billings
Investigational Site Number 840122, Chicago
Investigational Site Number 840119, Chicago
Investigational Site Number 804108, Kharkiv
Investigational Site Number 804105, Kharkiv
Investigational Site Number 840114, Springfield
Investigational Site Number 250108, Clermont-Ferrand
Investigational Site Number 276108, Saint Ingbert-Oberwürzbach
Investigational Site Number 276101, Heidelberg
Investigational Site Number 804101, Zaporozhie
Investigational Site Number 840110, West Jordan
Investigational Site Number 840105, Phoenix
Investigational Site Number 840113, Mesa
Investigational Site Number 840102, Tempe
Investigational Site Number 840112, Glendale
Investigational Site Number 840103, Northridge
Investigational Site Number 250103, Nanterre
Investigational Site Number 840118, Redlands
Investigational Site Number 840104, Temecula
Investigational Site Number 840116, Mission Viejo
Investigational Site Number 276104, Künzing
Investigational Site Number 276102, Bad Mergentheim
Investigational Site Number 642102, Ploieşti
Investigational Site Number 643103, Moscow
Investigational Site Number 643101, Moscow
Investigational Site Number 643107, Saint Petersburg
Investigational Site Number 643105, Saint Petersburg
Investigational Site Number 643110, Saint Petersburg
Investigational Site Number 642103, Timișoara
Investigational Site Number 642104, Reşiţa
Investigational Site Number 643104, Voronezh
Investigational Site Number 642105, Oradea
Investigational Site Number 643102, Samara
Investigational Site Number 643108, Vladimir
Investigational Site Number 643106, Nizhny Novgorod
Investigational Site Number 840107, Tempe
Investigational Site Number 840101, Sea Girt
Investigational Site Number 124102, Brampton
Investigational Site Number 124108, Coquitlam
Investigational Site Number 124106, Etobicoke
Investigational Site Number 124113, Kelowna
Investigational Site Number 124110, Laval
Investigational Site Number 124103, Newmarket
Investigational Site Number 124101, Oakville
Investigational Site Number 124111, Saint Romuald
Investigational Site Number 124104, Thornhill
Investigational Site Number 124105, Toronto
Investigational Site Number 124112, Vancouver
Investigational Site Number 203106, Újezd u Brna
Investigational Site Number 250102, Menton
Investigational Site Number 276105, Pirna
Investigational Site Number 616106, Bytom
Investigational Site Number 616102, Gdansk
Investigational Site Number 616101, Krakow
Investigational Site Number 616103, Lublin
Investigational Site Number 616108, Oświęcim
Investigational Site Number 616105, Wroclaw
Investigational Site Number 616104, Wroclaw
Investigational Site Number 616107, Wroclaw
Investigational Site Number 642101, Bucharest
Investigational Site Number 724104, Barcelona
Investigational Site Number 724103, Barcelona
Investigational Site Number 724101, Hostalets de Balenyà
Investigational Site Number 804103, Kyiv
Lead Sponsor
Sanofi
INDUSTRY